Pds biotech announces preliminary biomarker study results in subset of advanced hpv-positive head and neck cancer patients at esmo

Princeton, n.j., oct. 23, 2023 (globe newswire) -- pds biotechnology corporation (nasdaq: pdsb) (pds biotech or the company), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the company's proprietary t cell activating platforms, today announced immune response data from a preliminary analysis of a subset of patients in versatile-002, the phase 2 clinical trial evaluating the safety and efficacy of pds0101 in combination with merck's anti-pd-1 therapy keytruda® (pembrolizumab) in patients with human papillomavirus (hpv)16-positive recurrent or metastatic head and neck squamous cell carcinoma (hnscc). the data presented during the european society for medical oncology congress 2023 (esmo congress 2023) provided preliminary insight to the pre-existing immune responses in advanced hpv-positive hnscc patients and potential changes to the immune profile after treatment.
PDSB Ratings Summary
PDSB Quant Ranking